Skip to main content
. Author manuscript; available in PMC: 2020 Jan 28.
Published in final edited form as: J Control Release. 2018 Dec 18;294:237–246. doi: 10.1016/j.jconrel.2018.12.031

Figure 3.

Figure 3.

Effect of DDND systems with N/P ratios of 60, 40 and 20 on (A) Capan-1 and (B) CD18/HPAF PC cell viability. Cell Density: 1×104 cell/well. miRNA Dose: 10 pmol. Gemcitabine dose: 3 μg/well. Incubation time: 72h. The same letters represent statistically significant differences between cases (p<0.05).*, ** and *** represent the statistically significant differences of the DDND system with N/P ratios of 60 against all controls (p<0.05).